MAP Pharmaceuticals, Inc. (MAPP) Tops Q2 EPS by 10c

MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q2 loss of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $2.55 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Scholastic Corp (SCHL) Misses Q1 EPS by 23c